Wolfgang Hiddemann

Research.com Recognitions

• 2023 - Research.com Medicine in Germany Leader Award

Overview

Best Publications

• Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

  Bruce D. Cheson;John M. Bennett;Kenneth J. Kopecky;Thomas Büchner

  3855
  Citations

• A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma

  James O. Armitage

  3470
  Citations

• Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group

  Wolfgang Hiddemann;Michael Kneba;Martin Dreyling;Norbert Schmitz

  1928
  Citations

• Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease.

  Susanne Schnittger;Claudia Schoch;Martin Dugas;Wolfgang Kern

  1438
  Citations

• Dominant-negative mutations of CEBPA , encoding CCAAT/enhancer binding protein-α (C/EBPα), in acute myeloid leukemia

  Thomas Pabst;Beatrice U. Mueller;Pu Zhang;Hanna S. Radomska

  1131
  Citations

• A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

  Eva Hoster;Martin Dreyling;Wolfram Klapper;Christian Gisselbrecht

  1060
  Citations

• Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group.

  Martin Schrappe;Alfred Reiter;Wolf-Dieter Ludwig;Jochen Harbott

  930
  Citations

• Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype

  Susanne Schnittger;Claudia Schoch;Wolfgang Kern;Cristina Mecucci

  908
  Citations

• Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86

  A Reiter;M Schrappe;WD Ludwig;W Hiddemann

  895
  Citations

• The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas : results of a prospective randomized study of the German Low-Grade Lymphoma Study Group

  Roswitha Forstpointner;Martin Dreyling;Roland Repp;Sandra Hermann

  846
  Citations

• Immunochemotherapy With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Significantly Improves Response and Time to Treatment Failure, But Not Long-Term Outcome in Patients With Previously Untreated Mantle Cell Lymphoma: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG)

  Georg Lenz;Martin Dreyling;Eva Hoster;Bernhard Wörmann

  821
  Citations

• A 17-gene stemness score for rapid determination of risk in acute leukaemia

  Stanley W. K. Ng;Amanda Mitchell;James A. Kennedy;James A. Kennedy;James A. Kennedy;Weihsu C. Chen

  788
  Citations

• Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network

  Martin Dreyling;Georg Lenz;Eva Hoster;Achiel Van Hoof

  753
  Citations

• Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study

  Rolf D Issels;Lars H Lindner;Jaap Verweij;Peter Wust

  722
  Citations

• Obinutuzumab for the First-Line Treatment of Follicular Lymphoma

  Robert Marcus;Andrew Davies;Kiyoshi Ando;Wolfram Klapper

  696
  Citations

• Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry

  Alessandro Pastore;Vindi Jurinovic;Robert Kridel;Eva Hoster

  683
  Citations

• Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG).

  Roswitha Forstpointner;Michael Unterhalt;Martin Dreyling;Hans-Peter Böck

  650
  Citations

• Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia

  Stephen Johnson;Alister G. Smith;Helmut Löffler

  640
  Citations

• Treatment of Older Patients with Mantle-Cell Lymphoma

  H. C. Kluin-Nelemans;Eva Hoster;Olivier Hermine;J. Walewski

  619
  Citations

• Convention on nomenclature for DNA cytometry

  Wolfgang Hiddemann;Johannes Schumann;Michael Andreef;Barthel Barlogie

  251
  Citations